Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Processa Pharmaceuticals Inc (PCSA) USD0.0001

Sell:$7.20 Buy:$8.00 Change: $0.07 (0.89%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.07 (0.89%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.07 (0.89%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development of drug products that are intended to provide treatment for patients who have unmet medical need condition that effects survival or the patient’s life and no treatment options. The Company has three drugs in various stages of clinical development. The Company’s advanced product candidate, PCS499, is an oral tablet that is a deuterated analog for metabolites of pentoxifylline (PTX or Trental). It has completed a Phase 2A trial for PCS499 and recruiting for a Phase 2 trial. PCS12852 is a potent and selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Its PCS6422 is an oral, potent, selective and irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD). The Company also has PCS11T, which is a lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan.

Contact details

7380 Coca Cola Dr Ste 106
United States
+1 (443) 7763133

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$115.94 million
Shares in issue:
15.60 million
United States
US dollar

Key personnel

  • David Young
    Chairman of the Board, Chief Executive Officer, Founder
  • Wendy Guy
    Founder, Chief Administrative Officer
  • Sian Bigora
    Chief Development Officer, Founder
  • James Stanker
    Chief Financial Officer
  • R. Michael Floyd
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.